Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 218 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Anemia in Pregnancy Clear all

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Pegcetacoplan; Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Miami Lakes, Florida • Louisville, Kentucky + 4 more

Conditions: Thrombotic Microangiopathies
Interventions: OMS721; Biological
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Duarte, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Anemia of Chronic Kidney Disease
Interventions: Erythropoiesis-Stimulating Agent (ESA), Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 18
States / cities: Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more

Conditions: End Stage Renal Disease, Anemia
Interventions: Roxadustat, Epoetin Alfa, Placebo; Drug · Other
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more

Conditions: Anemia of Chronic Kidney Disease
Interventions: JTZ-951, Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 9
States / cities: Pine Bluff, Arkansas • Mountain View, California • Lauderdale Lakes, Florida + 6 more

Conditions: Anemia, Renal Insufficiency, Chronic
Interventions: Molidustat (BAY85-3934), Epoetin alfa/beta; Drug · Biological
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Azusa, California • Long Beach, California • Lynwood, California + 16 more

Conditions: Nocturnal Enuresis, Anemia, Sickle Cell
Interventions: Desmopressin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 8 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Twin Monochorionic Diamniotic Placenta
Interventions: Fetoscopy Sets for Anterior and Posterior Placentas; Device
Lead sponsor: Michael A Belfort; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pregnancy
Interventions: Néevo®/ NéevoDHA®; Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Corpus Christi, Texas

Conditions: Iron Deficiency Anemia of Pregnancy
Interventions: Ferrous Sulfate; Dietary Supplement
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Iron Deficiency Anemia of Pregnancy, Iron Malabsorption
Interventions: Iron dextran, Ferrous sulfate 325mg; Drug
Lead sponsor: Indiana University; Other
Eligibility: Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Indianapolis, Indiana • St Louis, Missouri

Conditions: Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions: Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements; Drug
Lead sponsor: University of Washington; Other
Eligibility: Up to 3 Days
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Disease, Sickle Cell Nephropathy
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Anemia in Pregnancy
Interventions: Masimo spot hemoglobin non-invasive monitor; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions: Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 23
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more

Conditions: Anemia Associated With Chronic Kidney Disease
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 2 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 4
States / cities: Chicago, Illinois • Omaha, Nebraska • New York, New York + 1 more

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 141
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more

Conditions: Anemia, Chronic Kidney Disease, Chronic Renal Failure
Interventions: peginesatide; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 14
States / cities: Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more

Conditions: Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD)
Interventions: Ferumoxytol, Iron Sucrose; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 38
States / cities: Pine Bluff, Arkansas • Azusa, California • Beverly Hills, California + 32 more

Conditions: Alpha Thalassemia Major, Hemoglobinopathy; With Thalassemia, Hemoglobinopathies, Fetal Anemia, Fetal Hydrops, Alpha; Thalassemia, Thalassemia Major, Thalassemia Alpha, A-Thalassemia
Interventions: in utero hematopoietic stem cell transplantation; Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Weeks to 26 Weeks
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atypical Hemolytic-Uremic Syndrome
Interventions: Eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Burlington, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more

Conditions: Renal Insufficiency, Chronic, Iron-Deficiency Anemia
Interventions: Ferric maltol, Placebo; Drug · Other
Lead sponsor: Shield Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 27
States / cities: Peoria, Arizona • Phoenix, Arizona • Prescott, Arizona + 24 more

Conditions: Thrombocytopenia, Neutropenia, Lymphopenia, Anemia
Interventions: TXA127, Placebo; Drug
Lead sponsor: Tarix Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Mobile, Alabama • Los Angeles, California • Orange, California + 3 more

Search by objective public record fields.

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

Desmopressin for Bedwetting in Children With SCD

Safety and Efficacy of Fetoscopes Used in Fetoscopic Selective Laser Photocoagulation

Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)

Daily vs Intermittent Iron Therapy in Pregnancy

Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease

Non-invasive Spot Hemoglobin Measurement in the Outpatient Obstetric Clinic

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents

Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Peginesatide for Anemia in Chronic Hemodialysis Patients

Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis

In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer